Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adavosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Adavosertib overview

Adavosertib (AZD-1775, MK-1775) is under development for the treatment of advanced refractory lymphoma and multiple myeloma, advanced solid tumors including head and neck squamous cell carcinoma, advanced and metastatic pancreatic adenocarcinoma, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer, oral cancer, cervical cancer, vaginal cancer, recurrent endometrial cancer, metastatic triple negative breast cancer(as a second and third line therapy), relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome,definitive chemoradiation esophageal and gastroesophageal junction cancer, small-cell lung cancer and platinum-resistant TP53-mutated fallopian tube and primary peritoneal cancer, metastatic colorectal cancer and adenocarcinoma of the pancreatic cancer. It is a small molecule administered orally in the form of capsule. It acts by targeting Wee1. It was also under development for the treatment of non-squamous non-small-cell lung cancer. The drug candidate is a new molecular entity (NME).

It was under development for head and neck cancer, esophageal cancer and gastric cancer, epithelial ovarian, uterine cancer and solid tumors.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Adavosertib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.